Mizuho Markets Americas LLC Raises Stake in Kenvue Inc. (NYSE:KVUE)

Mizuho Markets Americas LLC raised its position in Kenvue Inc. (NYSE:KVUE) by 464.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,810,403 shares of the company’s stock after acquiring an additional 1,489,647 shares during the quarter. Kenvue makes up about 0.9% of Mizuho Markets Americas LLC’s holdings, making the stock its 27th biggest holding. Mizuho Markets Americas LLC’s holdings in Kenvue were worth $41,875,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in KVUE. Leo Wealth LLC lifted its position in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after buying an additional 481 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in shares of Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after acquiring an additional 492 shares during the period. Wolff Wiese Magana LLC raised its position in Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after purchasing an additional 501 shares during the last quarter. Marathon Capital Management boosted its stake in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares during the period. Finally, Poehling Capital Management INC. grew its position in Kenvue by 0.5% during the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock worth $1,908,000 after purchasing an additional 547 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Piper Sandler increased their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Deutsche Bank Aktiengesellschaft increased their price objective on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group began coverage on Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. JPMorgan Chase & Co. upped their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Royal Bank of Canada lowered Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Performance

Kenvue stock opened at $23.84 on Friday. The stock’s 50-day moving average is $22.75 and its 200-day moving average is $20.65. The company has a market cap of $45.70 billion, a price-to-earnings ratio of 43.34, a price-to-earnings-growth ratio of 2.10 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.13.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the business posted $0.31 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.